---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000157"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:31:20.420694+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BeiGene settles BRUKINSA patent litigation; generic entry no earlier than June 15, 2037

## Summary
- Settlement with MSN allows generic BRUKINSA in U.S. no earlier than June 15, 2037, subject to customary accelerations.
- Composition of matter patent expiring April 2034 was not challenged by MSN in the litigation.
- Patent litigation against Sandoz also dismissed; all ANDA suits for BRUKINSA now resolved.
- Parties filed joint stipulation to dismiss; settlement submitted to FTC and DOJ for review.

## SEC filing metadata
- accession: 0001651308-24-000157
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000157/0001651308-24-000157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000157/bgne-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000157
- JSON: https://secwatch.observer/filing/0001651308-24-000157.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.